Leyden Labs reports positive Phase 1 results for RIG-101, an investigational intranasal therapy designed to strengthen antiviral defenses and help prevent virus-triggered asthma exacerbations. The results support RIG-101’s advancement into Phase 2 clinical development.

In a new paper published in Science Translational Medicine, Leyden Labs reports landmark preclinical and clinical data supporting the development of their antibody-based nasal sprays to prevent influenza infection by neutralizing virus at portal …

In vivo influenza protection was achieved at a significantly lower antibody dose with intranasal compared to systemic administration  In contrast to what is observed with systemic administration, Leyden Labs’ lead influenza antibody CR9114 has …

The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic.

Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is a universal anti-hemagglutinin stem …

A new article from Leyden Labs has been published in the European Journal of Epidemiology.

Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and …

A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.